Robert Edward Sosnowski Net Worth

The estimated Net Worth of Robert Edward Sosnowski is at least $10.9 Tysiąc dollars as of 4 May 2010. Robert Sosnowski owns over 10,000 units of Cyclacel Pharmaceuticals Inc stock worth over $10,900 and over the last 16 years Robert sold CYCC stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Robert Sosnowski CYCC stock SEC Form 4 insiders trading

Robert has made over 1 trades of the Cyclacel Pharmaceuticals Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently Robert exercised 10,000 units of CYCC stock worth $4,400 on 4 May 2010.

The largest trade Robert's ever made was exercising 10,000 units of Cyclacel Pharmaceuticals Inc stock on 4 May 2010 worth over $4,400. On average, Robert trades about 2,500 units every 0 days since 2008. As of 4 May 2010 Robert still owns at least 10,000 units of Cyclacel Pharmaceuticals Inc stock.

You can see the complete history of Robert Sosnowski stock trades at the bottom of the page.

What's Robert Sosnowski's mailing address?

Robert's mailing address filed with the SEC is 200 CONNELL DRIVE, SUITE 1500, , BERKELEY HEIGHTS, NJ, 07922.

Insiders trading at Cyclacel Pharmaceuticals Inc

Over the last 19 years, insiders at Cyclacel Pharmaceuticals Inc have traded over $6,366,241 worth of Cyclacel Pharmaceuticals Inc stock and bought 3,400,245 units worth $14,147,428 . The most active insiders traders include Capital Ltd Portfolio Servi..., Austin W & Greenhouse David... oraz Kevin Ctang Capital Managem.... On average, Cyclacel Pharmaceuticals Inc executives and independent directors trade stock every 78 days with the average trade being worth of $115,984. The most recent stock trade was executed by Paul Mc Barron on 21 December 2023, trading 1,886 units of CYCC stock currently worth $6,262.

What does Cyclacel Pharmaceuticals Inc do?

cyclacel limited is a pharmaceuticals company located in 46-48 e smithfield, london, united kingdom.

Complete history of Robert Sosnowski stock trades at Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc executives and stock owners

Cyclacel Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Spiro George Rombotis,
  Pres, CEO & Exec. Director
• Dr. Judy H. Chiao,
  VP of Clinical Devel. & Regulatory Affairs
• Paul McBarron,
  Exec. VP, CFO, COO, Sec. & Exec. Director
• Dr. Mark H. Kirschbaum M.D.,
  Sr. VP & Chief Medical Officer
• Dr. Robert Westwood Ph.D.,
  Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel.
• Gill Christie,
  Director of HR
• Gregory T. Hradsky,
  Director
• Kevin Ctang Capital Managem...,
  
• Judy Chiao,
  V.P., Clin. Dev. & Reg. Aff.
• Nicholas G Bacopoulos,
  Director
• Christopher S Henney,
  Director
• David C Uprichard,
  Director
• Lloyd Sems,
  Director
• Sam L Barker,
  Director
• John Michael Middlecott Banham,
  Director
• Spiro George Rombotis,
  President and CEO
• Capital Ltd Portfolio Servi...,
  
• Robert J. Spiegel,
  Director
• Brian Schwartz,
  Interim Chief Medical Officer
• Daniel K Spiegelman,
  Director
• Austin W & Greenhouse David...,
  10% owner
• Stanley Morgan,
  10% owner
• Robert Edward Sosnowski,
  VP, Marketing & Sales
• James Edeerfield Capital Lp...,
  
• Willian Collins,
  General Manager
• Gregory Reyes,
  Senior VP, Research
• Pierre Legault,
  Director
• John Gordon Mc Vie,
  Director
• Robert Westwood,
  V.P., Chem. & Preclin. Dev.
• Jean Deleage,
  
• Robert Jackson,
  S.V.P. & Chief Scientific Offi
• Mark Kirschbaum,
  Chief Medical Officer
• Paul Mc Barron,
  See Remarks
• Karin L Walker,
  Director
• Kenneth M. Ferguson,
  Director